Akero Therapeutics
Dec 13, 2018
Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M
Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer’s drug Eli Lilly has remunerated USD 81 million upfront for the global rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclin...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
